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DNA methylation in a Scottish family
multiply affected by bipolar disorder and
major depressive disorder
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Abstract
Background: Bipolar disorder (BD) is a severe, familial psychiatric condition. Progress in understanding the aetiology of
BD has been hampered by substantial phenotypic and genetic heterogeneity. We sought to mitigate these confounders
by studying a multi-generational family multiply affected by BD and major depressive disorder (MDD), who carry an
illness-linked haplotype on chromosome 4p. Within a family, aetiological heterogeneity is likely to be reduced, thus
conferring greater power to detect illness-related changes. As accumulating evidence suggests that altered DNA
methylation confers risk for BD and MDD, we compared genome-wide methylation between (i) affected carriers of the
linked haplotype (ALH) and married-in controls (MIs), (ii) well unaffected haplotype carriers (ULH) and MI, (iii) ALH and
ULH and (iv) all haplotype carriers (LH) and MI.
Results: Nominally significant differences in DNA methylation were observed in all comparisons, with differences
withstanding correction for multiple testing when the ALH or LH group was compared to the MIs. In both comparisons,
we observed increased methylation at a locus in FANCI, which was accompanied by increased FANCI expression in the
ALH group. FANCI is part of the Fanconi anaemia complementation (FANC) gene family, which are mutated in Fanconi
anaemia and participate in DNA repair. Interestingly, several FANC genes have been implicated in psychiatric disorders.
Regional analyses of methylation differences identified loci implicated in psychiatric illness by genome-wide association
studies, including CACNB2 and the major histocompatibility complex. Gene ontology analysis revealed enrichment for
methylation differences in neurologically relevant genes.
Conclusions: Our results highlight altered DNA methylation as a potential mechanism by which the linked haplotype
might confer risk for mood disorders. Differences in the phenotypic outcome of haplotype carriers might, in part, arise
from additional changes in DNA methylation that converge on neurologically important pathways. Further work is
required to investigate the underlying mechanisms and functional consequences of the observed differences in
methylation.
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Background
Bipolar disorder (BD) is severe psychiatric condition
characterised by recurrent episodes of depression and
mania. BD is highly heritable (h2 = 0.85 [1]), and in re-
cent years, progress has been made in identifying risk-
associated variants through genome-wide association
studies (GWASs) (reviewed in [2]). These risk variants
are, however, of small effect and together only partially
explain BD’s heritability [3, 4].
Many of the associated variants for BD fall within
non-coding regions of the genome [5], implicating per-
turbed regulatory processes in the pathogenesis of this
condition. Consistent with this observation, gene expres-
sion studies have identified several changes in individ-
uals with BD [6, 7].
Some of these expression changes might be attribut-
able to altered DNA methylation, which has been ob-
served in individuals with BD, for example [8–12]. DNA
methylation levels at many sites are, at least in part,
under genetic control [13], indicating one potential
mechanism by which regulatory variants might confer
risk for BD. In addition, comparison of monozygotic
twins who are discordant for BD, or the related psy-
chiatric illness schizophrenia, has revealed several loci
showing significant differences in DNA methylation [14].
These differences might reflect the actions of environ-
mental risk factors, which are believed to contribute to
the imperfect concordance for BD observed in monozy-
gotic twins.
To date, case-control studies of DNA methylation in
BD have been limited either by a restricted focus on can-
didate genes [8–10, 12] or the study of a small group of
unrelated individuals [15, 16]. Here, we capitalise on the
increase in homogeneity conferred by the study of re-
lated individuals by assessing blood-based DNA methy-
lation in a large Scottish family multiply affected by BD
and major depressive disorder (MDD). Increased aetio-
logical homogeneity within this family may confer
greater statistical power to detect phenotypically relevant
differences in DNA methylation. Previous analyses of
this family have identified a ~20 Mb haplotype on
chromosome 4p15-16, which shows linkage to BD and
MDD (henceforth referred to as the linked haplotype
(LH)) [17, 18] (maximum LOD score = 4.41). Ongoing
analysis of the family, which now includes additional
individuals, suggests that the LH acts in conjunction
with genome-wide polygenic risk to confer risk for BD
(Clarke et al., manuscript in preparation).
Here, we assessed the hypothesis that the LH confers
risk via an effect on DNA methylation and identified
four loci showing differences in methylation in carriers
of the LH that withstood correction for multiple testing.
Furthermore, as some carriers of the LH do not develop
BD or MDD, we attempted to identify differences in
DNA methylation that represent additional risk and/or
protective loci that act in concert with the linked haplo-
type to determine an individual’s phenotype. In this
comparison, no individual locus remained significant
after correction for multiple testing; however, collect-
ively, the most differentially methylated loci were found
to map to genes involved in neurologically relevant func-
tions. Together, these analyses aimed to assess the
contribution of genetically and environmentally driven
changes in DNA methylation to the development of BD
and MDD.
Results
Overview of research strategy
Genome-wide DNA methylation was measured in mem-
bers of a large family multiply affected by BD and MDD,
using the Infinium HumanMethylation450 BeadChip.
Three groups of individuals were considered: affected
(diagnosed with either BD or MDD) carriers of the
linked haplotype (ALH; n = 10; (BD n = 5; MDD n = 5));
unaffected carriers of the linked haplotype (ULH; n = 10)
and unaffected, non-haplotype-carrying married-in con-
trols (MIs; n = 9). A series of comparisons was per-
formed: ALH vs. MI, ULH vs. MI, ALH vs. ULH and LH
(combined ALH and ULH) vs. MI. These comparisons
permitted us to assess our hypotheses that (i) the linked
haplotype confers an increase in risk for major affective
disorders via an effect on DNA methylation and (ii)
DNA methylation at certain loci correlates with the
presence/absence of illness in haplotype carriers, reflect-
ing the involvement of additional risk/protective loci. To
gain an insight into the potential consequences of differ-
ential methylation, gene ontology analysis was carried
out to identify biological processes and functions over-
represented amongst the most significantly differentially
methylated loci.
Quality control and data filtering
As the performance of some probes on the array is
known to be affected by the presence of single nucleo-
tide polymorphisms (SNPs) or cross-hybridisation, these
probes were removed prior to data analysis. Firstly,
17,955 probes in which the target CpG is located within
2 bp of a SNP (minor allele frequency ≥5 %) and 29,093
probes predicted to cross-hybridise [19] were removed
from the dataset. The overall success of DNA methyla-
tion profiling was then assessed by considering plots
representing the output of quality control probes, which
measure the success of various stages of the profiling
process. This revealed incomplete bisulphite conversion
in two samples, which were omitted from downstream
analyses. Finally, 2937 probes were removed as they had
more than five samples with a bead count of less than
three and/or ≥1 % of the samples had a detection p value
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of >0.05. At the end of this filtering process, the dataset
comprised 435,889 probes measured in nine ALHs (BD
n = 5; MDD n = 4), ten ULHs and eight MIs (Additional
file 1: Table S1).
Selection of normalisation method
Twelve normalisation methods available in the R pack-
age wateRmelon [20] were ranked according to their
ability to reduce noise attributable to technical error
(Additional file 1: Table S2). Daten 2 was identified as
the optimum normalisation method.
Assessment of between-group differences in cell
composition
Due to the presence of cell type-specific DNA methyla-
tion patterns, individual differences in blood cellular
composition can confound the assessment of methyla-
tion. As such, between-group differences in estimated
cellular proportions were assessed. No significant differ-
ences were observed (p ≥ 0.276).
Surrogate variable analysis
To reduce the potentially confounding effects of unmeas-
ured and/or unmodelled variables, surrogate variables
(SVs) were estimated [21]. This resulted in the identifica-
tion of six significant SVs, which were fitted as covariates
in the differentially methylated position (DMP) analysis.
Identification of DMPs
Linear regression analysis was performed to assess DNA
methylation at the 435,889 probes retained after data
filtering. This analysis revealed four loci to be signifi-
cantly differentially methylated following multiple testing
correction (false discovery rate (FDR)-adjusted p ≤ 0.1)
when comparing the LH group with the MI group
(Table 1; Additional file 1: Table S3; Fig. 1). These loci
map to the following: an intron in FANCI, 147 bp down-
stream of NBEAL2, the shared promoter region of
GCOM1 and MYZAP and an intronic region of AHRR.
Two of these loci, FANCI and NBEAL2, were also found
to be significantly differentially methylated when com-
paring the ALH group with the MI group (Table 2;
Additional file 1: Table S4; Fig. 1). Comparison of (i) the
ULH group with the MI group and (ii) the ALH group
with the ULH group did not yield any significant results
following multiple testing correction (Additional file 1:
Tables S5 and S6).
Assessment of FANCI expression
As a preliminary step in investigating the consequences
of the increase in methylation at a site within FANCI ob-
served in the LH and ALH groups (when compared with
the MI group), we assessed FANCI expression. Expres-
sion was measured in lymphoblastoid cell lines (LCLs)
obtained from the same individuals who were assessed
for DNA methylation. Three individuals (two ALH and
one MI) were excluded as they were deemed to be out-
lier samples. FANCI expression was, therefore, compared
between eight ALH, ten ULH and eight MIC individuals
(Additional file 1: Table S1). A significant increase in
FANCI expression was observed in the ALH group when
compared to the MI group using a linear regression model
that covaried for gender (p = 0.0423, fold change = 1.21;
Fig. 2). A non-significant increase in expression was ob-
served when comparing the LH and MI groups (p = 0.206,
fold change =1.13).
Identification of DMRs
Correlation between DNA methylation at neighbouring
probes on the 450 K array permits methylation changes
to be considered at a regional level [22]. This approach
reduces the impact of any individual poor-performing
probes, rendering the results more robust. For each
comparison (ALH vs. MI, ULH vs. MI, ALH vs. ULH
and LH vs. MI), nominally significant probes (p ≤ 0.05)
from the DMP analyses were assessed for differentially
methylated regions (DMRs). Details of the number of
probes entered into the analyses and the number of
DMRs identified for each comparison are presented in
Table 3. The results from these analyses are presented in
their entirety in Additional file 1: Tables S7–S10.
DMRs were compared with regions previously impli-
cated in the pathogenesis of BD, MDD or schizophrenia
through GWAS. A literature search identified five
studies reporting genome-wide significant associations
for BD [3, 23–26] and one study reporting genome-wide
Table 1 Differentially methylated positions identified when comparing the LH group with the MI group
Probe ID Chr. Coordinatea Gene β differenceb p value Adjusted p valuec
cg12858231 15 89846095 FANCI 0.0356 2.54 × 10−7 0.0560
cg09354556 3 47051341 NBEAL2d −0.0551 2.99 × 10−7 0.0560
cg22708112 15 57883393 GCOM1/MYZAP −0.105 3.85 × 10−7 0.0560
cg12251573 5 421644 AHRR 0.149 6.58 × 10−7 0.0717
ahg19/GRCh37
bLH β mean-MI β mean
cBenjamini-Hochberg false discovery rate-adjusted p value
dThis probe maps 147 bp downstream of NBEAL2
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significant associations for MDD [27]. Genome-wide sig-
nificant associations for schizophrenia were identified
from three studies [28–30]. Four DMRs overlapping
with regions previously implicated in schizophrenia were
identified [28–30]. These regions map to CACNB2 (LH
vs. MI p = 1.84 × 10−4), the extended MHC (ULH vs. MI
p = 1.37 × 10−4), C11orf87 (ALH vs. ULH p = 5.32 × 10−5)
and an intergenic region between CYP2D7 and TCF20
(LH vs. MI p = 1.49 × 10−5; ULH vs. MI p = 1.85 × 10−5).
These regions of overlap are detailed in Table 4.
Three DMRs are particularly notable for their signifi-
cance and the involvement of a large number of probes.
These are a 829-bp hypomethylated region (spanning
29 probes) located at the developmentally important
HOXA5 locus, observed in the ALH, ULH and LH
groups when compared with the MI group (ALH vs.
MI p = 3.65 × 10−62; ULH vs. MI p = 5.85 × 10−61; LH
vs. MI p = 1.62 × 10−77); a 847-bp hypermethylated region
(spanning either 22 (LH) or 24 (ALH) probes) located to-
wards the 5′ end of RNF39, observed in the ALH and LH
groups when compared with the MI group (ALH vs.
MI p = 3.45 × 10−32; LH vs. MI p = 2.11 × 10−29) and a
1461-bp hypomethylated region (spanning 22 probes)
encompassing the promoter regions and the first exons of
Fig. 1 Bee swarm plots showing DNA methylation levels (β values) for the four loci identified as being differentially methylated in the LH vs. MI
comparison (a FANCI, b NBEAL2, c GCOM1/MYZAP, d AHRR). Methylation values are shown for the married-in control (MI), affected carriers of the
linked haplotype (ALH), unaffected carriers of the linked haplotype (ULH) and all linked haplotype carriers (LH) groups. *FDR-adjusted p ≤ 0.1
Table 2 Differentially methylated positions identified when comparing the ALH group with the MI group
Probe ID Chr. Coordinatea Gene β differenceb p value Adjusted p valuec
cg09354556 3 47051341 NBEAL2d −0.0633 1.93 × 10−7 0.0711
cg12858231 15 89846095 FANCI 0.0390 3.26 × 10−7 0.0711
ahg19
bALH β mean-MI β mean
cBenjamini-Hochberg false discovery rate-adjusted p value
dThis probe maps 147 bp downstream of NBEAL2
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AGPAT1 and RNF5, observed in the ALH group com-
pared to the ULH group (p = 1.19 × 10−20).
Gene ontology analysis
In order to ascertain whether genes involved in particu-
lar biological processes, molecular functions or cellular
components were overrepresented amongst the most
differentially methylated loci; gene ontology (GO) ana-
lysis was performed for each of the four comparisons,
ALH vs. MI, ULH vs. MI, ALH vs. ULH and LH vs. MI.
This resulted in the identification of several GO cate-
gories showing FDR-significant enrichment (q ≤ 0.1;
Additional file 1: Table S11–S21). Considering those GO
categories that are classified as pertaining to “biological
processes”, a theme common to all four comparisons
was development. Within this broad theme, GO cate-
gories relating to the development of the nervous system
(e.g. “regulation of nervous system development” (ALH
vs. MI q = 1.99 × 10−4; LH vs. MI q = 5.36 × 10−2),
“neuron projection guidance” (ULH vs. MI q = 1.17 × 10−2;
ALH vs. ULH q = 1.40 × 10−3) and “nervous system devel-
opment” (ALH vs. ULH q = 3.30 × 10−4)) ranked highly for
all four comparisons. Continuing the theme of enrichment
for neurologically relevant GO categories, both the ALH
vs. MI and LH vs. MI comparisons revealed a significant
enrichment for genes belonging to the “molecular func-
tion” GO category “voltage-gated ion channel activity”
(ALH vs. MI q = 1.19 × 10−2; LH vs. MIC q = 6.00 × 10−2).
Of those GO categories considered to relate to “cellular
components”, the LH vs. MI comparison yielded several
results relating to neurons and synapses, with the category
“neuron part” attaining a q value of 7.72 × 10−2. Interest-
ingly, in light of the important role believed to be played
by calcium signalling in psychiatric illness [31], a significant
enrichment for “calcium ion binding” was found when
comparing the ALH and ULH groups (q = 1.23 × 10−4).
Discussion
Several members of a large Scottish family carry a 20
Mb haplotype on chromosome 4p that confers risk for
BD and MDD [17, 18]. Here, we sought to further our
understanding of the mechanisms mediating the adverse
effects of the LH by studying DNA methylation, an epi-
genetic mark found to be altered in individuals with psy-
chiatric disorders (e.g. [14, 32–34]). Moreover, as some
carriers of the linked haplotype remain well, we aimed to
identify changes in DNA methylation that might reflect
the involvement of additional risk/protective loci. To the
best of our knowledge, this represents the first family-
based genome-wide study of DNA methylation in the
major affective disorders, BD and MDD. By studying re-
lated individuals who share a known genetic susceptibility
locus, our study took advantage of the increase in
statistical power conferred by the reduced genetic and
aetiological heterogeneity expected in a single family com-
pared with larger case-control studies.
Analysis of carriers of the LH resulted in the identifi-
cation of four significantly differentially methylated loci,
when compared with a group of MI. These loci map to
an intron in FANCI, the GCOM1 and MYZAP promoter
region, an intron in AHRR, and 147 bp 3′ of NBEAL2.
The methylation differences at two of these loci, FANCI
and NBEAL2, were also significant when considering
only those carriers of the LH who had been diagnosed
with either MDD or BD. Although none of these loci
showed significant differential methylation when com-
paring the ALH and ULH groups, it is interesting to
note that the mean level of methylation in the ULH
group falls between those of the ALH and MI groups for
all four loci. This might suggest that possession of the
linked haplotype results in a change in methylation that
Fig. 2 Bee swarm plot showing normalised gene expression values
for FANCI in the married-in control (MI) and affected carriers of the
linked haplotype (ALH) groups. FANCI expression was measured in
lymphoblastoid cell lines using qRT-PCR and was normalised to the
geometric mean of ATP5B, RPLP0 and UBC. *p≤ 0.05
Table 3 Summary of differentially methylated region (DMR)
analyses
Comparison No. of probes included
in DMR analysisa
No. of DMRs
detected
ALH vs. MI 23,205 150
ULH vs. MI 20,599 120
ALH vs. ULH 16,755 49
LH vs. MI 23,433 156
aNominally significant probes (p ≤ 0.05) from the DMP analyses were entered
into a modified version of the champ.lasso function implemented in the
R package ChAMP [73]
Walker et al. Clinical Epigenetics  (2016) 8:5 Page 5 of 12
is further modified by additional susceptibility/protective
factors.
Increased whole blood FANCI methylation was accom-
panied by increased expression in LCLs from affected
carriers of the linked haplotype, further supporting the
notion that altered FANCI function might contribute to
the pathogenic effects of the LH. It is important to note
that we were unable to measure methylation and ex-
pression in the same tissue. This is a limitation of the
present study that precludes us from drawing any defini-
tive conclusions regarding the relationship between al-
tered methylation and expression. Future studies should
aim to characterise the relationship between FANCI ex-
pression and methylation in this family.
FANCI is a member of the Fanconi anaemia comple-
mentation (FANC) gene family. Mutations in these genes
can cause Fanconi anaemia, a rare genome instability
syndrome. Members of the FANC family act together in
the Fanconi anaemia pathway to repair DNA damage.
Phosphorylation of FANCI has been shown to act as a
trigger for this process [35], and siRNA-induced deple-
tion of FANCI has been shown to induce a higher base-
line rate of DNA damage and reduced capacity to mend
double strand breaks [36].
Genetic variation in members of the Fanconi anaemia
pathway has been implicated in neurodevelopmental
phenotypes and psychiatric illness. FANCD2/FANCI-as-
sociated nuclease 1 (FAN1) is a repair nuclease that is
recruited to sites of interstrand crosslinks by interacting
with a FANCD2-FANCI complex. The FAN1 gene is
located at 15q13.3, a region affected by multiple micro-
deletions that predispose to a number of clinical pheno-
types, including schizophrenia [37, 38], autism spectrum
disorder (ASD), attention deficit hyperactivity disorder,
epilepsy and intellectual disability [39]. An exome
sequencing study identified a cluster of rare non-
synonymous variants located within a 20-kb window that
spans several functional domains of FAN1, which were
associated with schizophrenia with depressive features,
schizoaffective disorder and ASD [40]. More recently, a
large-scale GWAS found a genome-wide significant asso-
ciation between the FANCL locus and schizophrenia [28].
GCOM1 forms part of the GRINL1A complex tran-
scription unit, which comprises three groups of tran-
scripts [41]. GCOM1, which is a read-through transcript
of MYZAP and POLR2M, shows similarity in amino acid
sequence to the NR1 N-methyl-D-aspartate (NMDA)
subunit-interactor Yotiao [42] and the amino termini of
the NR2 and NR3 NMDA subunits [41]. Evidence for an
interaction between GCOM1 and NR1 has been identi-
fied in the rat brain, where GCOM1 facilitates NMDA
receptor activity [43]. The known roles of NMDA recep-
tors in neurodevelopment, neuroplasticity and excitotoxi-
city [44], together with the evidence implicating altered
NMDA function in psychiatric illness [45, 46] render
GCOM1 a strong functional candidate. Interestingly, a
three nucleotide deletion within GRINL1A has been de-
tected in an exome sequencing study of sporadic ASD [47].
We detect decreased methylation at a site that falls
within a DNase hypersensitive site (DHS) in the GCOM1/
MYZAP promoter region [48]. DHSs are indicative of an
open chromatin structure, which makes DNA accessible
to binding by transcription factors. Characterisation of the
genomic locations of GWAS-significant variants has
revealed that 76.6 % of associated non-coding SNPs are
located within DHSs or are in complete linkage disequilib-
rium with a SNP located in a DHS [5]. This suggests that
the observed change in methylation might confer an effect
on GCOM1 and MYZAP expression; however, further
work is required to assess this possibility and to assess any
effects on NMDA receptor activity.
Consideration of our data at a regional level revealed a
hypermethylated region located within an intronic re-
gion of multiple CACNB2 isoforms and overlapping the
promoter region of a single CACNB2 isoform in the LH
group. Variation at the CACNB2 locus has been found
to increase risk for schizophrenia [28] and for the five
psychiatric disorders, schizophrenia, BD, MDD, ASD
and attention deficit hyperactivity disorder, included in a
recent cross-disorder GWAS [49]. The hypermethylated
region overlaps with a DHS and several chromatin im-
munoprecipitation (ChIP)-identified transcription factor
binding sites [48]. Taken together, it is possible that the
observed increase in methylation might exert an effect
Table 4 Overlap between DMRs and regions implicated in schizophrenia by a recent large-scale GWAS [28]
PGC SCZ regiona DMR coordinatesa DMR gene(s) DMR comparison DMR p value DMR directionb
Chr10:18681005-18770105 Chr10:18688985-18689948 CACNB2 LH vs. MI 1.84 × 10−4 Up
Chr22: 42548710-42548874 Chr22: 42548710-42548874 – LH vs. MI 1.49 × 10−5 Up
ULH vs. MI 1.85 × 10−5 Up
Chr11: 109285471-109610071 Chr11: 109294141-109294239 C11orf87 ALH vs. ULH 5.32 × 10−5 Up
Chr6: 28303247-28712247 Chr6: 28555640-28559522 Extended MHC ULH vs. MI 1.37 × 10−4 Down
ahg19/GRCh37
b“Up” indicates hypermethylation and “down” indicates hypomethylation compared to the reference group
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on the expression of the short CACNB2 isoform; how-
ever, this would need to be assessed experimentally.
Comparison of the affected and unaffected carriers of
the linked haplotype identified a region of hypomethyla-
tion upstream of HTR2A. This gene encodes the 5-HT2A
receptor, a target of both atypical antipsychotics [50] and
selective serotonin reuptake inhibitors [51]. Moreover,
variation in HTR2A has been associated with risk for
MDD by candidate gene studies (reviewed in [52]) and a
meta-analysis [53]. Another DMR of interest falls within
an intronic region of the mitotic spindle-assembly check-
point gene MAD1L1, adjacent to a region previously
associated with risk for schizophrenia and BD [28, 54].
MAD1L1 has been shown to be a target of another
schizophrenia-susceptibility gene, miR-137 [55]. A DMR
identified in the comparison of these two groups worth
noting for its potential functional relevance affects NPAS4.
We observed reduced methylation in the ALH group in a
region spanning the final exon of NPAS4. NPAS4 encodes
a brain-specific transcription factor, which is involved in
regulating the formation of inhibitory synapses [56].
Stress, a well-established risk factor for psychiatric illness
[57], has been shown to modulate NPAS4 methylation in
mice [58].
In order to investigate the biological systems poten-
tially impacted by the observed methylation changes,
GO analysis was performed. It is interesting to note the
presence of enrichment for GO categories pertaining to
neurodevelopment and neuronal function in all four
comparisons. This finding is particularly pertinent in
light of the fact that it was necessary to assess DNA
methylation differences relevant to the pathogenesis of
BD and MDD in a non-neuronal tissue. Our findings in-
dicate that it may be possible to detect methylation dif-
ferences relevant to nervous system function in the
blood, despite the existence of between-tissue differences
in DNA methylation [59, 60].
When performing GO analysis of methylation array
data, a single p value must be selected to represent each
gene. We decided to select the most significant p value for
any locus within a gene as a methylation change at an in-
dividual locus has the potential to confer an effect on gene
function. As such, genes that contain more CpG sites are
more likely to have their function altered by a change in
methylation and are, therefore, more likely to obtain a
more significant p value. A confounding factor, however,
is that genes that are targeted by more probes also have a
greater likelihood of obtaining a more significant p value
by chance due to multiple testing. The conflation of these
two factors presents an analytical challenge as correcting
for multiple testing risks reducing true biological signal.
This is a limitation of currently available methods for GO
analysis of methylation data, which must be considered
when interpreting our findings.
As each blood cell type has a distinct methylation pro-
file, it was important to assess the existence of system-
atic between-group variation in cell type distribution,
which could confound the detection of methylation dif-
ferences [61, 62]. We did not observe any between-
group differences in estimated cell type proportions,
suggesting that variation in cell type distribution would
be unlikely to exert a large effect on the differences ob-
served in our sample. Moreover, by performing surro-
gate variables analysis (SVA), we were able to fit a set of
SVs in our analyses that controlled for all unmodelled
sources of variation, including cell type distribution [21].
Together, the set of SVs produced by SVA efficiently
represent the effects of all unmeasured or unmodelled
confounding variables on DNA methylation whilst pro-
tecting the primary variable of interest. As such, SVA
minimises the number of covariates that must be in-
cluded, thus helping to avoid model overfitting prob-
lems. With regards to modelling the effects of cell type
distribution, SVA confers the advantage of negating the
need to decide which cell types to include.
Another factor that should be considered when inter-
preting our findings is that affected carriers of the linked
haplotype were ill and taking medication prior to their
blood sample being obtained for methylation analysis.
As drug treatments for MDD and/or BD have previously
been shown to alter DNA methylation [63–67], it is pos-
sible that DNA methylation in this group was affected
by medication. To the best of our knowledge, however,
methylation at the sites found to be differentially
expressed in the current study has not been shown to be
affected by relevant drug treatments [63, 66, 67]. More-
over, the fact that the mean methylation level in the
ULH group falls between the means of the MI and
ALH groups for the four significant LH vs. MI loci
argues against medication being a primary driver of
our results.
The small size of the sample studied here is likely to
represent a limitation of the study. Although our ap-
proach of studying a large family benefits from reduced
aetiological heterogeneity, it is likely that some changes
remain undetectable due to insufficient power. In an at-
tempt to maximise our chances of detecting illness-
relevant changes in methylation, we used a significance
threshold of FDR-adjusted p ≤ 0.1. It is, of course, pos-
sible, however, that some of our results are false posi-
tives. Future studies should expand upon the work
presented here, perhaps by leveraging the increased
power conferred by the study of a relevant quantitative
phenotype. Ultimately, the synthesis of results obtained
through family studies with the results of larger case-
control studies, together with downstream functional
analyses are likely to be important steps in unravelling
the epigenetic contribution to psychiatric disorders.
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Conclusions
We have found evidence for altered blood DNA methy-
lation in carriers of a haplotype linked to BD and MDD.
Many affected genes have neuronal roles, participating
in neurodevelopment and ion channel activity. Our
observation that significant single locus methylation
differences are found in haplotype carriers regardless of
affectation status is consistent with our previous finding
of reduced cognitive function in haplotype carriers but
no difference in cognitive function between affected and
unaffected carriers of the haplotype [68]. Nevertheless,
through gene ontology analysis, we did find evidence
that differences in DNA methylation between affected
and unaffected haplotype carriers converge on neuro-
logically relevant functions. Taken together, our findings
suggest a scenario whereby the presence of the linked
haplotype confers multiple effects on DNA methylation,
which are in turn modified by additional genetic and/or
environmental influences that fine-tune an individual’s
risk of developing a mood disorder.
Methods
This study was approved by the Multicentre Research
Ethics Committee for Scotland, and appropriate in-
formed consent was obtained from the human subjects.
Sample
The individuals included in this study were selected
from a previously described large Scottish family multi-
ply affected by BD or MDD [17, 18]. A ~20 Mb haplo-
type located on chromosome 4p has previously been
found to segregate with illness in this family with a max-
imum LOD score of 4.41 [18]. Carriers of the haplotype
were grouped according to illness-status, resulting in
two groups: affected (either BD or MDD) carrier of the
disease-linked haplotype (ALH) and unaffected carrier of
the disease-linked haplotype (ULH). An additional group
of well married-in controls (MI) who do not carry the
disease-linked haplotype was included for comparison.
In total, ten ALH, ten ULH and nine MI individuals
were assessed.
Extraction of blood DNA
Blood (9 ml) was collected in an EDTA tube. DNA was
extracted at the Wellcome Trust Clinical Research Facility
at the University of Edinburgh, using the Nucleon
BACC2 Genomic DNA Extraction Kit (Thermo Fisher
Scientific, Loughborough, UK), following the manufac-
turer’s instructions.
Genome-wide methylation profiling
Whole blood genomic DNA (500 ng) was treated with
sodium bisulphite using the EZ-96 DNA Methylation
Kit (Zymo Research, Irvine, California), following the
manufacturer’s instructions. DNA methylation was assessed
using the Infinium HumanMethylation450 BeadChip
(Illumina Inc, San Diego, California), according to the
manufacturer’s protocol. Samples were assigned to chips
such that, as far as possible, group (ALH, ULH or MI) and
gender were counter-balanced across chips.
The resultant raw intensity (.idat) files were read into R
using the minfi package [69], which was used to perform
initial quality control assessments. Subsequently, filtering
of poor-performing samples and sites was performed.
Samples were removed from the dataset if: (i) they failed
any of the quality control assessments carried out in minfi
or (ii) ≥1 % sites had a detection p value of >0.05. Probes
were removed from the dataset if: (i) they were located
within two base pairs of SNP with a minor allele frequency
of ≥5 %; (ii) they were predicted to cross-hybridise [19]
and (iii) they had more than five samples with a bead
count of less than three or (iv) ≥1 % samples had a detec-
tion p value of >0.05.
The data was normalised using the Daten 2 method,
selected using the R package wateRmelon [20]. Daten 2 in-
volves adjusting the background difference between type I
and type II assays (by adding the offset between type I and
II probe intensities to type I intensities). A linear model is
incorporated at this stage to eliminate positional effects.
Between-array quantile normalisation is then performed
for the methylated and unmethylated signal intensities
separately (type I and type II assays normalised together).
Prior to downstream analyses, M-values, defined as
M-value = log2((M + 100)/(U + 100)), where M repre-
sents the methylated signal intensity and U represents the
unmethylated signal intensity, were calculated for the nor-
malised data. For ease of interpretation, the data were
converted to β-values (β-value = 2M/(2M + 1)) prior to
presentation.
Assessment of between-group differences in the whole
blood cellular composition
In order to assess between-group differences in the cel-
lular composition of whole blood samples, estimated cell
counts for B-lymphocytes, granulocytes, monocytes,
natural killer cells, CD4+ T-lymphocytes and CD8+
T-lymphocytes were generated using the estimate
CellCounts function in minfi. This function imple-
ments Jaffe and Irizarry’s [62] modified version of
Houseman’s [61] algorithm. Between-group differences
in cell composition were assessed using Student’s t
tests. A p value of ≤0.05 was deemed to represent a
significant between-group difference.
Identification of significant surrogate variables
DNA methylation can be affected by many sources of
variation, and it is, therefore, important to account for
these variables when assessing differential methylation.
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A complicating factor is that many sources of variation
are unknown or unmeasured. Moreover, even when po-
tential sources of variation are measured, it can be un-
clear how best to model these potential confounding
variables [21]. Surrogate variable analysis (SVA) identi-
fies a set of significant SVs that together represent vari-
ation in DNA methylation that is not attributable to the
primary variable of interest. These SVs are then fitted as
covariates in the linear models implemented to identify
DMPs. Covarying for the identified SVs controls for
sources of unmeasured/unmodelled variation (e.g. age,
genetic relatedness, smoking status, cell composition),
which might otherwise confound the relationship be-
tween DNA methylation and the independent variable of
interest [21, 70]. A key advantage of SVA is that it per-
mits complex relationships between confounders and
DNA methylation, for example, interactions between
multiple confounding variables. SVA was carried out
using the “be” method with the R package SVA [71].
Identification of differentially methylated positions
DMPs were then identified using the R package limma
[72] by fitting linear models with the outcome variable
“M-value” and the predictor variables “group” (ALH,
ULH or MI) and “gender”, together with the significant
SVs identified by SVA. The following comparisons were
carried out as follows: (i) ALH and MI, (ii) ULH and MI,
(iii) ALH and ULH and (iv) a combined linked haplotype
carrier group (ALH and ULH; henceforth referred to as
LH) and MI. Correction for multiple testing was imple-
mented using the Benjamini-Hochberg false discovery
rate (FDR), with adjusted p values of ≤0.1 deemed to be
significant.
Identification of differentially methylated regions
Differentially methylated regions (DMRs) were identified
using a modified version of the champ.lasso function im-
plemented in the R package ChAMP [73]. DMRs were
defined as regions containing three or more adjacent
probes within a defined lasso region showing unidirec-
tional changes in methylation that attained nominal sig-
nificance (unadjusted p ≤ 0.05) in the DMP analysis. The
lasso region was set to 2 kb and was scaled according to
the local genomic/epigenomic landscape in order to ac-
count for uneven probe spacing across the genome [73].
DMRs were merged with neighbouring DMRs where
they were separated by less than 1 kb, using the
“minDmrSep” parameter in the champ.lasso function.
P values were estimated for each DMR as described by
Butcher et al. [73]. Briefly, Stouffer’s method was used to
combine individual probe p values, which were weighted
by the underlying correlation structure of the M-
values. P values from correlated probes were down-
weighted whilst p values from uncorrelated probes were
up-weighted. DMRs with p values meeting a Benjamini-
Hochberg FDR-corrected threshold of ≤0.05 were in-
cluded in the final DMR lists.
Comparison of DMRs with GWAS results
DMRs were assessed for overlap with regions previously im-
plicated in BD, MDD and the related condition, schizophre-
nia, by GWAS. A literature search was carried out using
PubMed (on 7 October 2015) to identify case-control
GWAS studies and GWAS meta-analyses involving individ-
uals with either BD, MDD or schizophrenia. Only GWAS
results attaining genome-wide significance (p ≤ 5 × 10−8)
were considered. Significantly associated genes/regions from
the GWAS studies were defined as per the original study.
Overlap was defined as either complete or partial overlap
between the DMR and a GWAS associated gene/region.
Lymphoblastoid cell line culture and extraction of RNA
Human Epstein-Barr virus (EBV)-transformed LCLs
were derived from blood lymphocytes obtained from
family members at the European Collection of Cell
Cultures (http://www.phe-culturecollections.org.uk/col-
lections/ecacc.aspx). LCLs were maintained in Roswell
Park Memorial Institute medium with 10 % foetal bovine
serum at 37 °C and 5 % CO2.
Total RNA was extracted using the RNeasy Mini Kit
(Qiagen, Manchester, UK), according to the manufac-
turer’s instructions. An on-column DNase digest step was
performed using the RNase-Free DNase Set (Qiagen,
Manchester, UK), according to the manufacturer’s instruc-
tions. RNA quantity and quality were assessed using the
Agilent Bioanalyzer at the WTCRF. The Agilent Bioanalyzer
reports RNA integrity numbers (RINs), which indicate
how intact an RNA sample is (1 = completely degraded,
10 = completely intact). Sample RINs ranged from 8.6 to
10, indicating that the RNA was suitable for use in
qRT-PCR [74].
qRT-PCR assessment of Fanconi anaemia,
complementation group I (FANCI) expression
RNA (1 μg) was reverse transcribed using the Transcriptor
First Strand cDNA Synthesis Kit (Roche) using random
hexamer primers, according to the manufacturer’s
instructions.
cDNA samples were diluted by a factor of 1/100.
FANCI expression was assessed using a TaqMan Gene
Expression Assay (Hs01105308_m1, Applied Biosystems
by Thermo Fisher, Loughborough, UK). Briefly, 4.5 μl
cDNA was added to 5 μl TaqMan Universal PCR Master
Mix, No AmpErase UNG (2×) (Applied Biosystems) and
0.5 μl 20× TaqMan Gene Expression Assay (Applied
Biosystems by Thermo Fisher, Loughborough, UK) in a
384-well plate. qPCRs were performed on a 7900HT
PCR system with the following assay conditions: 15 s at
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95 °C, followed by 1 min at 60 °C for 40 cycles. FANCI
expression was normalised to the geometric mean of the
expression levels of three reference genes, ATP5B,
RPLP0 and UBC, which were selected from an initial set
of seven using geNorm [75]. Assay details are described
in Additional file 1: Table S22. Each sample was
measured in technical triplicates and the mean of this trip-
licate used in downstream analyses. Outlier samples,
defined as data points falling outside of the range defined
by median ± 1.5 × inter-quartile range were excluded.
Differences in FANCI expression were assessed by lin-
ear regression, covarying for gender. A p value of ≤0.05
was deemed to be significant.
Gene ontology analysis
Gene symbols representing all genes targeted by reliably
detected probes (n = 17,686 genes) were ranked accord-
ing to the probe p value calculated when identifying
DMPs (where an individual gene was targeted by mul-
tiple probes, the best p value was retained for GO
analysis) and ranked-list GO analysis performed using
GOrilla [76, 77]. GOrilla performs a hypergeometric test
to assign a p value to each GO category and then calculates
the Benjamini-Hochberg FDR to reflect the number of GO
categories assessed. GO categories with a q value ≤0.1 were
considered statistically significant.
Additional file
Additional file 1: Table S1. Sample demographic information for the
individuals included in this study. Table S2. Comparison of 12
normalisation methods. Table S3. Probes attaining an uncorrected p-value
of ≤ 0.05 in the comparison of individuals carrying the linked haplotype
(LH) and married in controls (MI), ranked by p-value. Table S4. Probes
attaining an uncorrected p-value of ≤ 0.05 in the comparison of affected
individuals carrying the linked haplotype (ALH) and married in controls (MI),
ranked by p-value. Table S5. Probes attaining an uncorrected p-value of
≤ 0.05 in the comparison of unaffected individuals carrying the linked
haplotype (ULH) and married in controls (MI), ranked by p-value. Table S6.
Probes attaining an uncorrected p-value of ≤ 0.05 in the comparison of
affected individuals carrying the linked haplotype (ALH) and unaffected
carriers of the linked haplotype (ULH), ranked by p-value. Table S7.
Differentially methylated regions (DMRs) identified in affected carriers of
the linked haplotye(ALH) compared to married in controls (MI), ranked by
p-value. Table S8. Differentially methylated regions (DMRs) identified in
carriers of the linked haplotye (LH) compared to married in controls (MI),
ranked by p-value. Table S9. Differentially methylated regions (DMRs)
identified in unaffected carriers of the linked haplotye (ULH) compared to
married in controls (MI), ranked by p-value. Table S10. Differentially
methylated regions (DMRs) identified in affected carriers of the linked
haplotye (ALH) compared to unaffected carriers of the linked haplotype
(ULH), ranked by p-value. Table S11. Significantly enriched molecular
process gene ontology (GO) categories identified in the ALH vs. MI
comparison. Table S12. Significantly enriched biological function gene
ontology (GO) categories identified in the ALH vs. MI comparison. Table
S13. Significantly enriched cellular component gene ontology (GO)
categories identified in the ALH vs. MI comparison. Table S14. Significantly
enriched molecular process gene ontology (GO) categories identified in the
ULH vs. MI comparison. Table S15. Significantly enriched biological function
gene ontology (GO) categories identified in the ULH vs. MI comparison.
Table S16. Significantly enriched cellular component gene ontology (GO)
categories identified in the ULH vs. MI comparison. Table S17. Significantly
enriched molecular process gene ontology (GO) categories identified in the
ALH vs. ULH comparison. Table S18. Significantly enriched biological
function gene ontology (GO) categories identified in the ALH vs. ULH
comparison. Table S19. Significantly enriched molecular process gene
ontology (GO) categories identified in the LH vs. MI comparison. Table S20.
Significantly enriched biological function gene ontology (GO) categories
identified in the LH vs. MI comparison. Table S21. Significantly enriched
cellular component gene ontology (GO) categories identified in the LH vs.
MI comparison. Table S22. Details of the qRT-PCR assays used to measure
the seven reference genes assessed for the stability of their expression using
geNorm [75]. XLSX 8646 kb)
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